These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 33070093)

  • 1. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
    Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
    Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
    Roy Burman D; Das S; Das C; Bhattacharya R
    Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological relevance of alternative splicing in hematologic malignancies.
    Szelest M; Giannopoulos K
    Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of alternative splicing in cancer.
    Singh B; Eyras E
    Transcription; 2017 Mar; 8(2):91-98. PubMed ID: 28005460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
    Urbanski LM; Leclair N; Anczuków O
    Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA Splicing and Cancer.
    Wang E; Aifantis I
    Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
    Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
    J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
    Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
    EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
    Bessa C; Matos P; Jordan P; Gonçalves V
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
    Zhang D; Meng F
    ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
    Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
    PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
    Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
    Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant RNA splicing and therapeutic opportunities in cancers.
    Yamauchi H; Nishimura K; Yoshimi A
    Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing and cancer: a systematic review.
    Zhang Y; Qian J; Gu C; Yang Y
    Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
    Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
    Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
    Sahin I; George A; Seyhan AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
    Dvinge H; Guenthoer J; Porter PL; Bradley RK
    Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.